NCT06365879View on ClinicalTrials.gov

To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria

PHASE3RecruitingINTERVENTIONAL

Enrollment

392

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

November 1, 2025

Study Completion Date

May 1, 2026

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG

CMAB007

300mg, SC, Q4W

DRUG

Xolair

300mg, SC, Q4W

Trial Locations (1)

Unknown

RECRUITING

Huashan Hospital, Shanghai

All Listed Sponsors

lead

Taizhou Mabtech Pharmaceutical Co.,Ltd

INDUSTRY